- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00168805
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 6-10 Days
연구 개요
상태
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Bryanston, 남아프리카
- 1160.25.02701 Boehringer Ingelheim Investigational Site
-
Randburg, 남아프리카
- 1160.25.02703 Boehringer Ingelheim Investigational Site
-
Sandton, 남아프리카
- 1160.25.02702 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Amsterdam, 네덜란드
- 1160.25.03102 Boehringer Ingelheim Investigational Site
-
Hilversum, 네덜란드
- 1160.25.03103 Boehringer Ingelheim Investigational Site
-
Hoofddorp, 네덜란드
- 1160.25.03101 Boehringer Ingelheim Investigational Site
-
Nijmegen, 네덜란드
- 1160.25.03104 Boehringer Ingelheim Investigational Site
-
Sittard, 네덜란드
- 1160.25.03105 Boehringer Ingelheim Investigational Site
-
Zwolle, 네덜란드
- 1160.25.03106 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Hellerup, 덴마크
- 1160.25.04571 Boehringer Ingelheim Investigational Site
-
Hørsholm, 덴마크
- 1160.25.04570 Boehringer Ingelheim Investigational Site
-
København NV, 덴마크
- 1160.25.04573 Boehringer Ingelheim Investigational Site
-
København S, 덴마크
- 1160.25.04574 Boehringer Ingelheim Investigational Site
-
Silkeborg, 덴마크
- 1160.25.04575 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bad Mergentheim, 독일
- 1160.25.04906 Caritaskrankenhaus
-
Erlangen, 독일
- 1160.25.04910 F.-A.-Universität Erlangen-Nürnberg
-
Frankfurt, 독일
- 1160.25.04904 Orthopädische Universitätsklinik
-
Garmisch-Partenkirchen, 독일
- 1160.25.04902 Klinikum Garmisch-Partenkirchen
-
Halle/Saale, 독일
- 1160.25.04911 Martin-Luther-Universität Halle-Wittenberg
-
Markgröningen, 독일
- 1160.25.04912 Orthopädische Klinik Markgröningen gGmbH
-
Rheinfelden, 독일
- 1160.25.04901 Kreiskrankenhaus
-
Sommerfeld, 독일
- 1160.25.04903 Hellmuth-Ulrici-Kliniken
-
Wiesbaden, 독일
- 1160.25.04905 Aukammklinik
-
-
-
-
-
Brussels, 벨기에
- 1160.25.03207 UVC Brugmann
-
Genk, 벨기에
- 1160.25.03209 ZOL St. Jan
-
Gent, 벨기에
- 1160.25.03206 Campus Sint-Lucas
-
Gent, 벨기에
- 1160.25.03208 UZ Gent
-
Hasselt, 벨기에
- 1160.25.03202 Virga Jesseziekenhuis
-
Herentals, 벨기에
- 1160.25.03203 AZ Sint Elisabeth
-
Lanaken, 벨기에
- 1160.25.03205 Ziekenhuis Oost-Limburg
-
Leuven, 벨기에
- 1160.25.03201 UZ Gasthuisberg
-
-
-
-
-
Falköping, 스웨덴
- 1160.25.04602 Boehringer Ingelheim Investigational Site
-
Göteborg, 스웨덴
- 1160.25.04601 Boehringer Ingelheim Investigational Site
-
Halmstad, 스웨덴
- 1160.25.04607 Boehringer Ingelheim Investigational Site
-
Kungälv, 스웨덴
- 1160.25.04603 Boehringer Ingelheim Investigational Site
-
Lidköping, 스웨덴
- 1160.25.04608 Boehringer Ingelheim Investigational Site
-
Linköping, 스웨덴
- 1160.25.04605 Boehringer Ingelheim Investigational Site
-
Mölndal, 스웨덴
- 1160.25.04604 Boehringer Ingelheim Investigational Site
-
Stockholm, 스웨덴
- 1160.25.04610 Boehringer Ingelheim Investigational Site
-
Varberg, 스웨덴
- 1160.25.04609 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Alcorcón (Madrid), 스페인
- 1160.25.03405 Boehringer Ingelheim Investigational Site
-
Barcelona, 스페인
- 1160.25.03403 Boehringer Ingelheim Investigational Site
-
Barcelona, 스페인
- 1160.25.03411 Boehringer Ingelheim Investigational Site
-
Hospitalet (Barcelona), 스페인
- 1160.25.03407 Boehringer Ingelheim Investigational Site
-
Jaén, 스페인
- 1160.25.03409 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1160.25.03401 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1160.25.03402 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1160.25.03404 Boehringer Ingelheim Investigational Site
-
Madrid, 스페인
- 1160.25.03406 Boehringer Ingelheim Investigational Site
-
Móstoles (Madrid), 스페인
- 1160.25.03408 Boehringer Ingelheim Investigational Site
-
Valencia, 스페인
- 1160.25.03410 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Linz, 오스트리아
- 1160.25.04304 Boehringer Ingelheim Investigational Site
-
Wels, 오스트리아
- 1160.25.04303 Boehringer Ingelheim Investigational Site
-
Wien, 오스트리아
- 1160.25.04302 Boehringer Ingelheim Investigational Site
-
Wr. Neustadt, 오스트리아
- 1160.25.04301 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bologna, 이탈리아
- 1160.25.03906 Boehringer Ingelheim Investigational Site
-
Parma, 이탈리아
- 1160.25.03905 Boehringer Ingelheim Investigational Site
-
Pavia, 이탈리아
- 1160.25.03901 Boehringer Ingelheim Investigational Site
-
Piacenza, 이탈리아
- 1160.25.03903 Boehringer Ingelheim Investigational Site
-
Reggio Emilia, 이탈리아
- 1160.25.03904 Boehringer Ingelheim Investigational Site
-
Treviso, 이탈리아
- 1160.25.03902 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Brno-Bohunice, 체코 공화국
- 1160.25.42004 Boehringer Ingelheim Investigational Site
-
Chomutov, 체코 공화국
- 1160.25.42010 Boehringer Ingelheim Investigational Site
-
Havlickuv Brod, 체코 공화국
- 1160.25.42009 Boehringer Ingelheim Investigational Site
-
Kladno, 체코 공화국
- 1160.25.42002 Boehringer Ingelheim Investigational Site
-
Kolin, 체코 공화국
- 1160.25.42006 Boehringer Ingelheim Investigational Site
-
Ostrava, 체코 공화국
- 1160.25.42003 Boehringer Ingelheim Investigational Site
-
Plzen, 체코 공화국
- 1160.25.42001 Boehringer Ingelheim Investigational Site
-
Pradubice, 체코 공화국
- 1160.25.42007 Boehringer Ingelheim Investigational Site
-
Prague 8, 체코 공화국
- 1160.25.42005 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kielce, 폴란드
- 1160.25.04804 Boehringer Ingelheim Investigational Site
-
Krakow, 폴란드
- 1160.25.04806 Boehringer Ingelheim Investigational Site
-
Krakow, 폴란드
- 1160.25.04807 Boehringer Ingelheim Investigational Site
-
Warsaw, 폴란드
- 1160.25.04803 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Amiens cedex 1, 프랑스
- 1160.25.03304 Boehringer Ingelheim Investigational Site
-
Annecy, 프랑스
- 1160.25.03307 Boehringer Ingelheim Investigational Site
-
La Rochelle, 프랑스
- 1160.25.03305 Boehringer Ingelheim Investigational Site
-
Paris cedex 14, 프랑스
- 1160.25.03301 Boehringer Ingelheim Investigational Site
-
Poitiers cedex, 프랑스
- 1160.25.03306 Boehringer Ingelheim Investigational Site
-
Roubaix cedex, 프랑스
- 1160.25.03303 Boehringer Ingelheim Investigational Site
-
Soyaux, 프랑스
- 1160.25.03302 Boehringer Ingelheim Investigational Site
-
St Etienne cedex 2, 프랑스
- 1160.25.03309 Boehringer Ingelheim Investigational Site
-
Strasbourg cedex 2, 프랑스
- 1160.25.03308 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Helsinki, 핀란드
- 1160.25.35803 Boehringer Ingelheim Investigational Site
-
Jyväskylä, 핀란드
- 1160.25.35802 Boehringer Ingelheim Investigational Site
-
Oulu, 핀란드
- 1160.25.35801 Boehringer Ingelheim Investigational Site
-
Seinäjoki, 핀란드
- 1160.25.35804 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Budapest, 헝가리
- 1160.25.03603 Boehringer Ingelheim Investigational Site
-
Békéscsaba, 헝가리
- 1160.25.03607 Boehringer Ingelheim Investigational Site
-
Gyula, 헝가리
- 1160.25.03601 Boehringer Ingelheim Investigational Site
-
Kecskemét, 헝가리
- 1160.25.03604 Boehringer Ingelheim Investigational Site
-
Szeged, 헝가리
- 1160.25.03602 Boehringer Ingelheim Investigational Site
-
Székesfehérvár, 헝가리
- 1160.25.03605 Boehringer Ingelheim Investigational Site
-
-
-
-
Australian Capital Territory
-
Garren, Australian Capital Territory, 호주
- 1160.25.06108 Boehringer Ingelheim Investigational Site
-
-
New South Wales
-
Kogarah, New South Wales, 호주
- 1160.25.06106 Boehringer Ingelheim Investigational Site
-
Lismore, New South Wales, 호주
- 1160.25.06110 Boehringer Ingelheim Investigational Site
-
-
South Australia
-
Bedford Park, South Australia, 호주
- 1160.25.06105 Boehringer Ingelheim Investigational Site
-
Toorak Gardens, South Australia, 호주
- 1160.25.06107 Boehringer Ingelheim Investigational Site
-
Woodville, South Australia, 호주
- 1160.25.06109 Boehringer Ingelheim Investigational Site
-
-
Victoria
-
Box Hill, Victoria, 호주
- 1160.25.06104 Boehringer Ingelheim Investigational Site
-
Clayton, Victoria, 호주
- 1160.25.06102 Boehringer Ingelheim Investigational Site
-
Malvern, Victoria, 호주
- 1160.25.06101 Boehringer Ingelheim Investigational Site
-
Ringwood East, Victoria, 호주
- 1160.25.06103 Boehringer Ingelheim Investigational Site
-
Windsor, Victoria, 호주
- 1160.25.06113 Boehringer Ingelheim Investigational Site
-
-
Western Australia
-
Perth, Western Australia, 호주
- 1160.25.06111 Boehringer Ingelheim Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria
Inclusion criteria (selected):
- Patients (18 years or older) scheduled to undergo a primary, unilateral, elect ive total knee replacement
- Written Informed Consent
Exclusion criteria
Exclusion criteria (selected):
- Patients with an excessive risk of bleeding, for example because of history of bleeding diathesis major surgery or trauma within the last 3 months history of haemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, arteriovenous (AV) malformation or aneurysm clinically relevant bleeding or gastric / duodenal ulcer within the last 6 months treatment with anticoagulants within 7 days prior to joint replacement surgery or anticipated need during the study treatment period thrombocytopenia.
- Active malignant disease or current cytostatic treatment
- Known severe renal insufficiency
- Liver disease expected to have any potential impact on survival, or elevated aspartate aminotransferase (AST) or alanine transaminase (ALT) > 2x upper limit of normal
- Recent unstable cardiovascular disease or history of myocardial infarction within the last 3 months
- Pre-menopausal women who are pregnant or nursing, or are of child-bearing pote ntial and are not practising or do not plan to continue practising acceptable me thods of birth control
- Allergy to radio opaque contrast media or iodine, heparins (incl. heparin indu ced thrombocytopenia) or dabigatran
- Contraindications to enoxaparin
- Participation in a clinical trial during the last 30 days
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: dabigatran etexilate 220 mg
220 mg once daily
|
150 mg once daily
220 mg once daily
|
실험적: dabigatran etexilate 150 mg
150 mg once daily
|
150 mg once daily
220 mg once daily
|
활성 비교기: enoxaparin
40 mg once daily
|
1일 1회 40mg
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period
기간: First administration until 6-10 days
|
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients. |
First administration until 6-10 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period
기간: 3 months
|
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
|
3 months
|
Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period
기간: First administration until 6-10 days
|
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee
|
First administration until 6-10 days
|
Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period
기간: First administration until 6-10 days
|
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee
|
First administration until 6-10 days
|
Number of Participants With Total Deep Vein Thrombosis During Treatment Period
기간: First administration until 6-10 days
|
Total Deep Vein Thrombosis as adjudicated by the VTE events committee
|
First administration until 6-10 days
|
Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period
기간: First administration until 6-10 days
|
Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee
|
First administration until 6-10 days
|
Number of Participants With Pulmonary Embolism During Treatment Period
기간: First administration until 6-10 days
|
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee
|
First administration until 6-10 days
|
Number of Participants Who Died During Treatment Period
기간: First administration until 6-10 days
|
All cause death, as adjudicated by the VTE events committee
|
First administration until 6-10 days
|
Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period
기간: First administration until 6-10 days
|
Major bleeding events were defined as
Clinically-relevant was defined as
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above. |
First administration until 6-10 days
|
Blood Transfusion
기간: Day 1
|
Blood transfusion for treated and operated patients on Day of surgery.
|
Day 1
|
출혈량
기간: 1일차
|
수술 중 치료 및 수술 환자의 실혈량.
|
1일차
|
실험실 분석
기간: 연구 종료까지의 첫 번째 투여
|
임상적으로 유의미한 이상 가능성이 있는 환자의 빈도.
|
연구 종료까지의 첫 번째 투여
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Rosencher N, Noack H, Feuring M, Clemens A, Friedman RJ, Eriksson BI. Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials. Thromb J. 2012 Jun 18;10(1):9. doi: 10.1186/1477-9560-10-9.
- Eriksson BI, Dahl OE, Rosencher N, Clemens A, Hantel S, Kurth AA. Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis. Thromb Res. 2012 Dec;130(6):871-6. doi: 10.1016/j.thromres.2012.08.315. Epub 2012 Sep 17.
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
혈전색전증에 대한 임상 시험
-
Beijing Friendship Hospital알려지지 않은대장암 환자에서 Perioperiative Venous Thromboembolism(VTE)의 발생률
dabigatran etexilate에 대한 임상 시험
-
Vanderbilt University Medical CenterBoehringer Ingelheim모집하지 않고 적극적으로LAA(Left Atrial Appendage) 장치 폐쇄 후 단기 Dabigatran Etexilate에 이어 아스피린 단독 요법의 효능(DEA-LAA 연구). (DEA-LAA)심방세동 | 좌심방 부속기 혈전증 | 장치 관련 혈전 | 와치맨 LAA 폐쇄 장치미국
-
Huons Co., Ltd.알려지지 않은
-
Herlev and Gentofte HospitalDanish Society of Cardiology모병
-
Herlev and Gentofte HospitalDanish Society of Cardiology모병
-
Boehringer Ingelheim종료됨심장 판막 질환벨기에, 캐나다, 체코 공화국, 덴마크, 프랑스, 독일, 네덜란드, 노르웨이, 폴란드, 스웨덴
-
Boehringer Ingelheim종료됨
-
Insel Gruppe AG, University Hospital Bern완전한허혈성 뇌졸중벨기에, 아일랜드, 이스라엘, 독일, 인도, 영국, 오스트리아, 스위스, 핀란드, 노르웨이, 이탈리아, 포르투갈, 슬로바키아, 일본, 그리스
-
Odense University Hospital완전한